Expansion of AML Treatment Landscape Underscores Importance of Molecular Testing
The Rapidly Changing Landscape of AML Therapies: Molecular Testing Informs Optimal Targeted Therapies for AML Patients
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such as VIALE-A, as well as mutation-directed personalized therapy for determining whether a patient will benefit from induction chemotherapy. Dr. Zakharia emphasizes the importance of molecular testing for clinicians to provide optimal treatment with the availability of such a wide range of available targeted therapies.
Click here to learn more.
